Cytokinetics heart failure drug succeeds but slightly higher death rate seen -study

Reuters - 13/11/2020 - Cytokinetics Inc on Friday said a pivotal trial of the experimental heart failure drug it is developing with Amgen Inc showed a slightly higher rate of cardiovascular-related death for patients given the medicine compared to those on a placebo. Details presented at annual meeting of the American Heart Association (AHA) held virtually this year follow the release in October of initial results for the 8,256-patient trial. That announcement said the drug, omecamtiv mecarbil, met its main trial combination goal of reducing the risk of heart related death or need for hospitalization and other urgent care. The benefit, while statistically significant, was not deemed dramatic, with those events occurring in 37% of trial patients treated with the medicine versus 39.1% of the placebo group. Researchers said on Friday that 809, or 19.6%, of trial patients treated with omecamtiv mecarbil died, compared with 798, or 19.4%, of patients assigned to a...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 13 November, 202020 November, 2020